NMTC — Neuroone Medical Technologies Income Statement
0.000.00%
Last trade - 00:00- $29.64m
- $30.26m
- $3.45m
- 26
- 13
- 41
- 15
Annual income statement for Neuroone Medical Technologies, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.93 | 0.243 | 2.12 | 3.45 | 3.45 |
| Cost of Revenue | |||||
| Gross Profit | — | -0.033 | 1.88 | 1.95 | 1.08 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 8.85 | 10.5 | 12.2 | 15.4 | 15.3 |
| Operating Profit | -6.92 | -10.2 | -10 | -12 | -11.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -13.6 | -9.95 | -10 | -11.9 | -12.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -13.6 | -9.95 | -10 | -11.9 | -12.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -13.6 | -9.95 | -10 | -11.9 | -12.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -13.6 | -9.95 | -10 | -11.9 | -12.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.15 | -0.93 | -0.625 | -0.654 | -0.46 |